Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

MSHL

Marshall Edwards (MSHL)

Mei Pharma, Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MSHL
DataHoraFonteTítuloCódigoCompanhia
09/07/201215:41Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MSHLMei Pharma, Inc. (MM)
05/07/201217:03Edgar (US Regulatory)Prospectus filed pursuant to Rule 424(b)(3) (424B3)NASDAQ:MSHLMei Pharma, Inc. (MM)
02/07/201216:18Edgar (US Regulatory)Current report filing (8-K)NASDAQ:MSHLMei Pharma, Inc. (MM)
28/06/201210:00PR Newswire (US)Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")NASDAQ:MSHLMei Pharma, Inc. (MM)
04/06/201210:00PR Newswire (US)Marshall Edwards Presents Results From Clinical Trial Of Lead Oncology Drug Candidate ME-143NASDAQ:MSHLMei Pharma, Inc. (MM)
29/05/201210:00PR Newswire (US)Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344NASDAQ:MSHLMei Pharma, Inc. (MM)
25/05/201214:32Edgar (US Regulatory)Amended Statement of Beneficial Ownership (SC 13D/A)NASDAQ:MSHLMei Pharma, Inc. (MM)
15/05/201211:05Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:MSHLMei Pharma, Inc. (MM)
14/05/201210:00PR Newswire (US)Marshall Edwards Completes Rights Offering To StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
08/05/201210:00PR Newswire (US)Marshall Edwards Receives $4 Million Subscription From Novogen In Rights OfferingNASDAQ:MSHLMei Pharma, Inc. (MM)
25/04/201210:00PR Newswire (US)Marshall Edwards Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating CancerNASDAQ:MSHLMei Pharma, Inc. (MM)
10/04/201210:00PR Newswire (US)Marshall Edwards Receives FDA Approval of Investigational New Drug Application for Clinical Testing of Oncology Drug Candidat...NASDAQ:MSHLMei Pharma, Inc. (MM)
03/04/201210:00PR Newswire (US)Marshall Edwards Announces Data from Clinical Trial of ME-143 Selected for Presentation at ASCO Annual MeetingNASDAQ:MSHLMei Pharma, Inc. (MM)
28/03/201210:00PR Newswire (US)Marshall Edwards CEO to Present at Needham Healthcare ConferenceNASDAQ:MSHLMei Pharma, Inc. (MM)
27/03/201210:00PR Newswire (US)Marshall Edwards Receives Notice of Effectiveness for Rights Offering to StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
27/03/201207:02Edgar (US Regulatory)Notice of Effectiveness (EFFECT)NASDAQ:MSHLMei Pharma, Inc. (MM)
20/03/201209:55Edgar (US Regulatory)Securities Registration Statement (S-1/A)NASDAQ:MSHLMei Pharma, Inc. (MM)
19/03/201210:00PR Newswire (US)Marshall Edwards Announces Terms for Rights Offering to StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
06/03/201211:00PR Newswire (US)Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344NASDAQ:MSHLMei Pharma, Inc. (MM)
29/02/201211:00PR Newswire (US)Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock ConferenceNASDAQ:MSHLMei Pharma, Inc. (MM)
21/02/201212:00PR Newswire (US)Marshall Edwards Announces Rights Offering to StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
21/02/201209:57Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)NASDAQ:MSHLMei Pharma, Inc. (MM)
21/02/201209:11Edgar (US Regulatory)Securities Registration Statement (S-1)NASDAQ:MSHLMei Pharma, Inc. (MM)
14/02/201219:12Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:MSHLMei Pharma, Inc. (MM)
03/01/201212:00PR Newswire (US)Marshall Edwards Issued New Method of Use Patent for Lead Oncology Drug Candidate ME-344NASDAQ:MSHLMei Pharma, Inc. (MM)
29/12/201112:00PR Newswire (US)Marshall Edwards Adds $2 Million in Private PlacementNASDAQ:MSHLMei Pharma, Inc. (MM)
20/12/201112:00PR Newswire (US)Marshall Edwards Awarded Key Patent For Compositions Of Lead Oncology Drug CandidatesNASDAQ:MSHLMei Pharma, Inc. (MM)
22/11/201112:00PR Newswire (US)Marshall Edwards to Host Annual Meeting of StockholdersNASDAQ:MSHLMei Pharma, Inc. (MM)
10/11/201112:00PR Newswire (US)Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare ConferenceNASDAQ:MSHLMei Pharma, Inc. (MM)
28/10/201113:44Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:MSHLMei Pharma, Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:MSHL